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Abstract
Background: Totally implantable central venous access devices (intraports) are commonly used
in cancer patients to administer chemotherapy or parenteral nutrition. Rupture of intraport is a
rare complication.
Patients and methods: During 3 years period, a total of 245 intraports were placed in cancer
patients for chemotherapy. Four of these cases (two colon cancer and one each of pancreas and
breast cancer) had rupture of the intraport catheter, these forms the basis of present report.
Results: Mean time insitu for intraports was 164∀35 days. Median follow-up time was 290 days
and total port time in situ was 40180 days. The incidence of port rupture was 1 per 10,000 port
days.
Three of the 4 cases were managed by successful removal of catheters. In two of these the catheter
was removed under fluoroscopic control using femoral route, while in the third patient the
catheter (partial rupture) was removed surgically. One of the catheters could not be removed and
migrated to right ventricle on manipulations.
Conclusion:  Port catheter rupture is a rare but dreaded complication associated with
subcutaneous port catheter device placement for chemotherapy. In case of such an event the
patient should be managed by an experienced vascular surgeon and interventional radiologist, as in
most cases the ruptured catheter can be retrieved by non operative interventional measures.
Background
Totally implantable central venous access devices (intrap-
orts) are commonly used in patients with cancer to
administer chemotherapy, blood and blood products,
antibiotics, parenteral nutrition and to obtain blood sam-
ples for laboratory analysis. The catheter is usually placed
in the subclavian vein under local anesthesia. There are
many complications associated with this technique like
hemothorax, pneumothorax, pocket infection, infection
of the tunnel or the port, bleeding, hematoma and throm-
bosis of the catheter or the vein. A very rare complication
of the intraport catheter is rupture inside the subclavian
vein [1].
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The literature regarding common complications is
abound, however there is very little information on port
ruptures. Some attempts has been made to correlate these
with type of port used, site of placement, type of chemo-
therapy, duration of catheter use etc [2,3]. However, what
is ideal is still debatable. We report here 4 cases of intrap-
ort ruptures encountered in our practice.
Patients and methods
Between June 1995 and May 1998, 245 patients under-
went intraports insertions at the "Agii Anargiri" Antican-
cer Hospital of Kifissia, Athens, Greece, and were followed
up for possible device-related morbidity. Baseline demo-
graphic information and the indication for the placement
were obtained from the retrospective review of patients'
medical and operative reports. Follow-up continued till
the device was removed or the patient died. Follow-up
time ranged from 1 month to over 3 years. Port-A-Cath®
with titanium portal and detachable silicon rubber cathe-
ter (Arrow International™, USA) were used in all cases. All
patients requiring removal or replacement of the device,
prior to completion of the intended treatment were iden-
tified from the operative room and hospital records.
All intraports were inserted by percutaneous access tech-
nique to the subclavian vein. The tip of the catheter was
positioned in the superior vena cava or the right atrium.
The ports were then placed within a subcutaneous pocket
created on the anterior chest wall. The position was docu-
mented by immediate intraoperative chest roentgeno-
gram. Four of these patients had port rupture of which
three were complete and one partial, one of these ruptures
was accidental.
Routine removal of the subcutanous intraport was carried
out in the operating room under local anesthesia with
xylocaine 1% (10 cc). An incision was placed on the skin
in the area over the drum of the device. Then the drum
was prepared by cutting off the tissues that surround the
port. The port and the catheter were caught with Kocher
forceps. The tissues around the catheter were dissected
and the catheter was slowly pulled out. The catheter was
cut into three pieces and was sent for culture. Patients
were discharged after two hours of observation.
Results
Over a three year period between 1995 and 1998 a total of
245 port devices were fitted in cancer patients (139
females and 106 males). Mean age of the patients was 58
± 6.3 years. Total port time in situ was 40180 days, while
mean (SD) port time in situ was 164 (35) days.
After a median follow-up of 290 days (range 30–690
days) four ports ruptured, thus bringing the number of
fractures per 1000 port days to 0.01% or one rupture every
10,000 port days. Two patients had cancer of the colon
and one each had cancer of breast and pancreas. Both
patients with colonic cancer received 5 flurouracil and
leukovorin, patient with breast cancer received epirubicin
and paclitaxal and patient with pancreatic cancer received
gemcitabine, paclitaxal and cisplatinum. No correlation
was observed with type of chemotherapy or site of disease.
Three of the port ruptures were full and one partial one of
the ruptures was accidental (case 1). The detail of the cases
has been provided in next section. Three of the patients
survived for two years after the catheter removal, while the
fourth patient with accidental port rupture and whose
catheter was left behind in the right ventricle died of pro-
gressive disease two month later.
Case 1
A 65-years-old female with colonic cancer, received
intraport for chemotherapy administration. After 6
months due to the poor response to chemotherapy it was
decided to remove the catheter. During the manipulations
for removal, the catheter, accidentally ruptured at the
point of its entrance in to subclavian vein. The peripheral
part of the catheter remained in the vein, while only the
central part could be removed. Another attempt to
uncover the subclavian vein till superior vena cava failed.
Patient underwent thoracotomy for removal of remaining
catheter two days later. Superior vena cava was opened
and catheter removal was attempted, however, during this
process the catheter slipped into right atrium and further
attempts to retrieve it were abandoned. Patient was started
on anticoagulant treatment using enoxaparin sodium, 1
mg/kg/12 h for 5 days and 40 mg/day for further 14 days
in order to prevent thromboembolic event. The patient
died two months later due to progressive disease without
obvious complications related to the retained catheter.
Case 2
A 68-year-old female with colonic cancer received intrap-
ort for administration of chemotherapy. After one and a
half year of treatment it was decided to remove the cathe-
ter as the catheter has thrombosed due to non hepariniza-
tion. At the time of its removal the catheter ruptured at the
point of its entry to subclavian vein. The peripheral part of
the catheter remained in the vein. An unsuccessful
attempt was made to expose subclavian vein till superior
vena cava. Later this catheter migrated to right ventricle.
The catheter was removed using the technique of Yedlicka
et al [5], through the left femoral vein by advancing a ves-
sel catheter to right ventricle under fluoroscopic control.
The broken catheter was caught with endovessel forceps
and was removed through femoral vein.
Case 3
A 74-years-old female suffering from breast cancer under-
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chemotherapy. After fourteen months of treatment it was
decided to remove the catheter as the catheter had throm-
bosed. On attempted removal the catheter was found to
be ruptured at its entry to subclavian vein (Figure 1). Next
day, the broken part of the catheter was removed success-
fully under fluoroscopic control using the technique
described above for case 2 (Figure 2). No complications
were observed. The biomechanical analysis of removed
catheter showed a significant decrease in the elasticity of
the material (Figure 3).
Case 4
In a 56-year-old female patient with pancreatic carcinoma
underwent an intraport placement for chemotherapy.
Eight months later, the patient complained of pain in the
back during the administration of chemotherapy. A fluor-
oscopic examination showed partially broken catheter in
the vein while the other part was lying in the subcutane-
ous tissue. The catheter was removed from the subclavian
vein carefully to avoid complete rupture of the catheter.
Similar to case 3 above, the biomedical examination
showed a significant reduction in the elasticity of the cath-
eter material.
Discussion
Since Aubaniac first described the percutaneous central
venous catheterization in 1952, insertion of central
venous access devices for fluid administration has
increased rapidly. The total complication rate associated
Chest X-ray showing the port in correct position while the  catheter is not shown here Figure 1
Chest X-ray showing the port in correct position while the 
catheter is not shown here. The catheter had moved in the 
right atrium, from where it was removed fluoroscopically.
X-ray showing the intravascular catheter being fluoroscopi- cally removed by means of a special endo-vessel grasper Figure 2
X-ray showing the intravascular catheter being fluoroscopi-
cally removed by means of a special endo-vessel grasper.World Journal of Surgical Oncology 2004, 2:36 http://www.wjso.com/content/2/1/36
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with central venous catheter devices ranges from 0.4 to
29% [3,4,6].
Spontaneous rupture of the port catheters appears to be a
very rare and dreaded event. Biffi et al, in 1997 [1],
reported three cases of port catheter rupture out of 178
ports inserted by them. The incidence of port rupture was
estimated to be 1.68 % (0.09/1000 port days). In their
series the rupture occurred 66 days after the placement,
during a pause between subsequent chemotherapy cycles.
The symptoms consisted of palpitations and chest dis-
comfort in two while the third patient remained asympto-
matic. All the catheters in their series were removed by
interventional technique without any complications
[1,5].
The biomechanical analysis, of ruptured catheters in our
series showed a significant decrease in the elasticity of the
material. No correlation between changes of mechanical
properties of the material and specific chemotherapy
administrated through the port has been established so far
[7,8]. Even in our series all patients received differing
chemotherapy and no correlation was observed between
the agent and property of the material, this is also due to
smaller number of such events.
In case 1 the port catheter rupture was due to wrong
manipulations during catheter removal and accidental
cutting of peripheral part without first holding it in clamp.
The further catheter movement was induced by negative
intra-thoracic pressure during respiration [9]. Other
potential cause of catheter fracture could be incorrect fix-
ation of the catheter to the locking steel ring, repeated
high pressure injections to resolve clot formation, altera-
tion of the catheter mechanical properties etc. In two of
our cases decreased elasticity of the material was found
however one case could not be attributed to any know
cause. There was no correlation of port rupture with type
of chemotherapy or site of cancer probably due to only 4
events.
Ballarini  et al [10], suggested that catheter thrombosis
mainly occurs due to incorrect fixation of the locking steel
ring to the port where it is associated with rupture. The
estimated incidence of port catheter rupture and emboli-
zation varies from 0.9 to 1.7% of the cases [1,10-12]. It
was 1.65% in our series.
There is no controversy that the foreign bodies inserted in
the systematic circulation must be removed. This is best
achieved under fluoroscopy with specific catheters and
snare loops. Removal of intravascular material by means
of minimally invasive techniques presents excellent
results, while at the same time it minimizes morbidity and
mortality [13,14]. If such an attempts fail, open surgery
should be considered.
Conclusions
Intravascular rupture of subcutaneous port catheters is a
rare complication. Etiology still remains elusive, however
wrong placement has been advocated as the most impor-
tant cause. Other causes include catheter material faults
and alterations of the material's mechanical properties,
probably due to the administered substances; however,
(a) The ruptured catheter had been sent for biomechanical analysis that identified alteration of its elastic properties Figure 3
(a) The ruptured catheter had been sent for biomechanical analysis that identified alteration of its elastic properties. (b) The 
port removed by means of the open techniquePublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
World Journal of Surgical Oncology 2004, 2:36 http://www.wjso.com/content/2/1/36
Page 5 of 5
(page number not for citation purposes)
there is no data to support the effect of administered sub-
stances. Ruptured catheters are best removed by mini-
mally invasive radiological techniques.
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